iRadimed Corporation (NASDAQ:IRMD) Given Consensus Rating of "Buy" by Analysts

Key Points

• Analyst consensus: Five brokers rate iRadimed an average of "Buy" (including one strong‑buy) with a mean 12‑month price target of $120.
• Q1 beat and outlook: iRadimed beat estimates with non‑GAAP EPS of $0.49 and revenue of $21.98M, provided FY2026 EPS guidance of $2.06–$2.21, and raised its quarterly dividend to $0.20 ($0.80 annualized).
• Insider activity: CEO Roger Susi sold 5,000 shares for about $506,900 on March 16; insiders have sold 48,750 shares in the last 90 days while retaining roughly 36.8% ownership.

Shares of iRadimed Corporation (NASDAQ:IRMD - Get Free Report) have been given an average recommendation of "Buy" by the five brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $120.00.

Several research analysts have recently issued reports on IRMD shares. Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a research note on Thursday, April 2nd. Lake Street Capital reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th.

Insiders Place Their Bets

In related news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $101.38, for a total transaction of $506,900.00. Following the transaction, the chief executive officer owned 2,242,500 shares in the company, valued at $227,344,650. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 48,750 shares of company stock worth $4,708,950 in the last 90 days. 36.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRMD. CWM LLC increased its holdings in iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock valued at $64,000 after buying an additional 107 shares during the last quarter. Johnson Investment Counsel Inc. increased its holdings in iRadimed by 0.7% during the third quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider's stock valued at $1,839,000 after buying an additional 187 shares during the last quarter. Summit Global Investments increased its holdings in iRadimed by 2.7% during the third quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider's stock valued at $508,000 after buying an additional 188 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after buying an additional 234 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in iRadimed by 4.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider's stock valued at $567,000 after buying an additional 267 shares during the last quarter. Institutional investors own 92.34% of the company's stock.

iRadimed Stock Performance

Shares of NASDAQ IRMD opened at $87.15 on Friday. The firm's 50 day moving average price is $96.69 and its 200-day moving average price is $93.87. The company has a market cap of $1.11 billion, a PE ratio of 49.80 and a beta of 0.91. iRadimed has a 52-week low of $50.31 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, analysts forecast that iRadimed will post 1.94 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed's dividend payout ratio is 45.71%.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.